There have been major advances in the understanding and management of atherosclerotic cardiovascular disease (ASCVD). Central to these was the discovery of the role of cholesterol-containing lipoprotein particles in the atherosclerotic process and the development of lipid-lowering agents, particularly statins. Despite substantial and consistent evidence to support a causal link between statin use and prevention of ASCVD events, there is still debate regarding the appropriate administration of statins, particularly with regard to primary prevention.
Laing ST. High-Intensity StatinsGuideline Expectations and Clinical Application. JAMA. 2017;317(24):2543–2544. doi:10.1001/jama.2017.5781
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.